DRUG THERAPY IN AUTOIMMUNE THYROIDITIS

Michael I. SHEREMET1, Viktor O. SHIDLOVSKYI2, Anatoly D. BEDENYUK2, Oleksandr V. SHIDLOVSKYI2, Vitaliy V. MAKSYMYUK2, Nina P. TKACHUK3, Victor M. BATIG3, Tetiana A. GLUSHCHENKO3, Ivanna I. ABRAMCHUK3, Igor A. MALISHEVSKY4

1 Surgery Department No1, Bukovinian State Medical University, Ukraine
2 Surgery Department, I.Y. Horbachevsky State Medical University, Ukraine
3 Department of Therapeutic Stomatoloy, Bukovinian State Medical University
4 Department of Oncology and Radiology, Bukovinian State Medical University, Ukraine

Received 15 June 2018, Accepted 29 July 2018

https://doi.org/10.31688/ABMU.2018.53.3.10

ABSTRACT

Background. Autoimmune thyroiditis (AIT) is one of the unsolved problems of modern endocrinology, the etiology and pathogenesis being still insufficiently known.

Objectives. To study the effects of substitution, antioxidant and lymph-drainage therapy on the structure and function of the thyroid gland in patients with AIT and hypothyroidism.

Methods. We have identified 2 groups of patients with AIT and subclinical hypothyroidism. The first group – control group – included 20 patients who received substitution therapy with thyroxine. The second group included 33 patients who received a comprehensive treatment with thyroxine, alpha lipoic acid and Lymphomyosot.

Results. The use of substitution therapy with thyroxine and the proposed antioxidant and lymph drainage therapy in patients with AIT led to the improvement of the structure of the gland, reduced the activity of peroxide oxidation processes and the activity of pro-inflammatory cytokines, increased the level of antioxidant defense enzymes, normalized the number of aniline-positive lymphocytes, improved the lymphatic drainage function of the gland. Our results sustain the

RéSUMÉ

La thérapie medicamenteuse de la thyroïdite auto-immune

Introduction. La thyroïdite auto-immune est l’un des problèmes non résolus de l’endocrinologie moderne, car la question de son étiologie et de sa pathogénie est insuffisamment connue.

Objectifs. Étudier l’effet de la substitution, de la thérapie antioxydante et de drainage lymphatique chez les patients atteints d’AIT avec hypothyroïdie sur la structure et l’état fonctionnel de la glande thyroïde et le cours des processus auto-immuns.

Méthodes. Pour évaluer l’efficacité de la substitution, de la thérapie antioxydante et du drainage lymphatique afin de stabiliser l’état fonctionnel de la thyroïde et de supprimer l’activité des processus auto-immuns, nous avons identifié 2 groupes de patients atteints de thyroïdite auto-immune avec hypothyroïdie subclinique. Dans le groupe I (de contrôle) ont été inclus 20 patients qui ont reçu un traitement de substitution avec de la thyroxine, l’acide alpha-lipoïque et Lymphomyosot conformément au schéma élaboré.
INTRODUCTION

Autoimmune thyroiditis (AIT) is one of the most common autoimmune diseases. The incidence of AIT is increasing and accounts for a significant proportion of all thyroid pathology. Hypothyroidism is one of the most common consequences of AIT. Despite the importance of this pathology, until now there have not been effective methods of treatment of AIT or a unanimous opinion of specialists regarding the treatment of immunological disorders that will lead to AIT.

Free radical oxidation plays an important role in the development of cytodestructive processes in the pathogenesis of a large number of diseases, including autoimmune diseases of the thyroid gland. PO products can inhibit the synthesis of proteins, cause polymerization of the protein components of the membrane and DNA bases and alter vascular patency, inflammatory reaction and chemotactic activity of cells. Damage to nucleic acids usually occurs due to oxidative degradation of their bases and deoxyribose’s, which are involved in the formation of cross-links. Damage to the cytoplasmic membrane and the DNA of the immunocompetent cells that regulate the strength of the immune response is the greatest danger, mediated by the free radicals. These processes cause their premature death and breakdown of immunological tolerance, with the appearance of autoimmunity reactions and persistence of chronic inflammation.

AIT is characterized by severe thyroid infiltration by lymphocytes, neutrophils and macrophages, indicating the inflammatory response. These processes are confirmed by an increase in the number of pro-inflammatory cytokines that produce T-lymphocytes and macrophages. T-cytotoxic cells in interaction with thyroid cause their destruction.

Adequate and complete functioning of lymph drainage mechanisms is an essential condition for maintaining an organism’s homeostasis, ensuring its vital functions. Effective lymph drainage of the intercellular matrix facilitates the restoration of impaired interaction of the immune-endocrine system with the cells and tissues, in particular, the thyroid gland.

The goal of substitution hormone therapy in hypothyroidism, as a consequence of AIT, is the achievement of medication euthyroidism. In addition to standard substitution therapy, special attention is given to complex treatment with the use of drugs that regulate the activity of the PO and the system of antioxidant protection and improve lymph circulation in the thyroid gland. Such an integrated approach to treatment of AIT is supposed to have a positive effect.

There are reports of a positive effect from the use of ALA as a universal antioxidant, which functions on the membrane and inside the cell. ALA is a potent endogenous vitaminoid-antioxidant that...
regulates the metabolism of the body, participating as a coenzyme in the Krebs cycle. Considering these pharmacological properties of ALA, it is possible to expect a positive effect of its application for the treatment of AIT. There are few reports in the literature on the use of ALA in the treatment of AIT, and its results have different interpretations, which should be considered as appraisals.

Activating lymph drainage and restoring self-regulating processes in the thyroid tissue is an important and primary task, from the point of view of bioregulation approach to the treatment of AIT.

To achieve these goals and objectives, we used a comprehensive anti-homotoxic medication called lymphomyosot. According to the literature, its administration improves the drainage of the intercellular space, function of the immune and endocrine systems, activates lymph outflow and transport function of the matrix, normalizes immunological protection of the body, restores homogeneity in the matrix. At the same time there are additional positive effects: increased bioavailability of medications, shortening their application term, minimizing their side effects.

A brief analysis of literature data regarding the pathogenic substantiation of AIT treatment suggests that the treatment should be comprehensive and multi-purpose. This means that it should be aimed at drug-mediated compensation of hypothyroidism, improvement of lymph outflow from the thyroid gland and reduction of lymphoid infiltration, correction of lipid peroxidation and AOD processes.

**The objective of the study** was to establish the effect of substitution, antioxidant and lymph drainage therapy on the structure and functional state of the thyroid gland in patients with AIT and hypothyroidism.

**Material and methods**

The study involved 53 women aged between 26 – 62 years, with autoimmune thyroiditis, who were examined between January 2014 – December 2016 in the Chernivtsi Regional Endocrinological Dispensary, Ukraine.

To evaluate the effectiveness of substitution, antioxidant and lymph drainage therapy in order to stabilize the functional state of the thyroid gland and suppress the activity of autoimmune processes, the patients with autoimmune thyroiditis with subclinical hypothyroidism were divided into two groups. The first group (control) included 20 patients who received substitution therapy with thyroxine preparations. The second group included 33 patients who received comprehensive treatment using thyroxine preparations, ALA and lymphomyosot in accordance with the developed scheme.

The activity of peroxide oxidation (PO) and the state of antioxidant systems (AOS) was assessed before the treatment, after 6 months and after 3 years, in both groups, by determining the degree of oxidative modification of proteins (OMP), the activity of ceruloplasmin (CP) in the serum, the content of malonic aldehyde (MA), the activity of glutathione peroxidase (GPx), and catalase in erythrocytes, by conventional methods. In addition, the hormonal function of the thyroid gland, the level of antibodies to thyroperoxidase (AbTPO) were studied, as well as structural changes in the gland (volume of the gland, nodular formation), by ultrasound examination.

The content of lymphocytes bearing the apoptosis marker, the CD95 + receptor, the level of apoptosis in the population of peripheral blood lymphocytes, the content of tumor necrosis factor-α (TNF-α), the concentration of interferon-γ (IFN-γ) and interleukin-β (IL-β) were studied, too. These indicators were studied by means of standard diagnostic kits, with the technology recommended by the manufacturer.

In order to have a comparative assessment, the same indicators were studied in 25 healthy women, aged 21 to 42 years.

The scheme of treatment included thyroxine preparations in an individual dose, which provided the level of TSH within the reference values from 0.4 to 4.0 μIU/mL. ALA was administered in courses according to the standard scheme – 300 units per day for 10 days, then the tablets were dosed for 300 units for three months, with a repetition after six months. Lymphomyosot was administered 1.1 ml intramuscularly for five days, followed by five more injections every four days, and then 10 drops three times a day, sublingually (30 ml per course), were administered. Repeated administration of the drug was carried out every three months – five injections every four days, with the continuation of its sublingual administration.

**Results and discussion**

The results of laboratory tests showed that patients from both groups had almost identical clinical manifestations of AIT with hypothyroidism and changes in the studied parameters before the treatment.

Six months after the treatment, the general condition of patients in both groups improved. However, the patients in the control group continued to feel pressure on the anterior surface of the neck and
suffered from dry cough. The patients in the main group, with rare exceptions, did not have complaints and considered themselves to be healthier. At the same time, the levels of MA and OMP decreased in patients of the control group and did not change in the second one. In general, the changes in the mean values are not reliable. In patients of the main group, in all cases, a decrease in the level of MA and OMP was noted. The changes are reliable in the mean values compared to those before the observation (p <0.05, Table 1).

After three years, all the patients were examined. In the control group, part of the patients subjectively noticed a deterioration of their general condition: the thickening of the front surface of the neck increased, they kept feeling general fatigue, their body weight increased. 14 patients had an increase in MA by 1.5 - 4.8 μmol/L and OMP by 5.17 - 9 u.o.d. (units of optical density)/g of protein, and in 6 cases they practically did not change. According to the mean values in the group as a whole, compared to those of 6 months of observation, the changes are significant. Patients in the main group considered themselves healthy in the second one. In general, the changes in the mean values compared to those before the observation (p <0.05, Table 1).

Therefore, the studied parameters of activity of processes of PO in patients with AIT, during 6 months and 3 years of follow-up, in patients from the control group, indicate a gradual evolution of these processes, and in patients of the main group - their significant decrease.

While studying the activity of AOD enzymes in patients from the control and study groups prior to their admission to hospital, the reduction of these indicators in comparison with control patients was established (Table 2).

After 6 months of follow-up, in 16 patients in the control group, catalase levels increased by 3.9 - 9.7 μmol/ min • g, while in 4 cases they practically did not change; in 18 patients, the ceruloplasmin level increased by 1.9 - 6.8, and in 3 of them it decreased by 0.5 - 1.7 u.o.d./g of protein; the level of GPx in 17 patients increased by 4.5 - 8.8 μmol/ min • ng, and in 3 of them it did not change significantly compared with the rates before the admission. After 3 years of treatment in the control group of patients, the activity of the AOD enzymes continued to increase. The catalase level in 16 patients increased by 3.5 - 7.6 μmol/ min • g of protein, and in 4 of them it decreased by 1.3 - 4.1 μmol/ min • g of protein. The level of ceruloplasmin in 18 patients increased by 1.8 - 5.7 u.o.d. / g of protein, and in 2 patients it practically did not change for 6 months; the level of GPx in 16 cases increased by 3.8 - 7.7 μmol/ min • ng, and in 4 patients, it was at the level of the values for the period of 6 months of treatment.

In the control group, the mean value (M ± m) of catalase, ceruloplasmin and GPx increased for the period of 6 months and 3 years of observation, compared with those before the treatment. The changes are reliable only for the catalase value (Table 2).

In the main group, the catalase increased in 28 patients in the range from 4.5 to 28.5 μmol/ min • g of Hb during 6 months of treatment and in 5 patients this value remained at the previous level. The content of ceruloplasmin in 27 patients increased by 5.2 to 21.7 u.o.d. / g of protein, in 3 of them it decreased by 2.7 to 3.4 u.o.d. / g of protein and in 3 of them it remained at the previous level. The activity of GPx in 24 patients increased in some cases by 8.9 - 42.7 μmol/ min • g of Hb, in 6 patients it decreased by 4.7 - 11.5 μmol/ min • g and in other 3 it did not change. 3 years after the treatment, compared to the values of 6 months, the activity of catalase in 29 patients increased by 4.6 - 24.3 μmol / min • g of Hb, in 2 patients it decreased by 2.6 and - 4.3 μmol/ min • g of Hb and in other two it did not change. The level of ceruloplasmin in 30 patients increased by 11.2 to 23.4 u.o.d. / g of protein and in 3 cases it did not change. The GPx activity in 25 patients increased from 8.6 to 31.2 μmol / min • g of Hb, in 5 cases it decreased from 4.8 to 9.2 μmol/ min • g of Hb and in 3 cases it remained unchanged. In general, the mean values (M ± m) of catalase, ceruloplasmin and GPx increased compared with the values for the 6 months of observation, indicating the positive effect of treatment on the activity of the blood AOD system p <0.05 (Table 2).

Therefore, the studied blood AOD values in patients with AIT for 6 months and 3 years of follow-up in patients from the control group indicate a mild and insignificant increase in AOD rates, and in patients from the main group their significant growth.

Studying apoptosis values found a significant decrease in the number of annexin V-presenting lymphocytes. This proves the suppression of apoptosis. The correlation between the number of annexin V-presenting lymphocytes with an increased number of CD95 + lymphocytes prepared for apoptosis
confirms the probability of a disorder in the realization of Fas-induced apoptotic loss of lymphocytes in AIT. In addition, there was a reliable increase in the level of pro-inflammatory cytokines TNF-α, INF-γ and IL-1β in the blood serum.

Regarding the apoptosis rate in the patients of the control group, after 6 months of treatment the CD95+ content decreased by 1.5–4.2% in 23 patients; in 4 of them it increased by 0.8–2.7% and in 6 cases it remained the same. The percentage of annexin V+ lymphocytes in 25 patients decreased by 0.3–3.2%, in 5 cases it increased by 0.2–1.4% and in 3 patients it did not change. The activity of pro-inflammatory cytokines, including the content of TNF-α, decreased in 27 patients by 0.2–1.1 pg/mL, in 3 cases it did not change and in other 3 it increased by 0.2–0.5 pg/mL; the concentration of INF-γ in 22 patients decreased by 0.3–2.7 pg/mL, in 4 of them it did not change and in 7 cases it increased by 0.3–0.6 pg/mL; the level of IL-1β in 25 patients decreased from 0.1–0.6 pg/mL, in 3 of them it remained unchanged, in other 5 it increased by 0.2–0.5 pg/mL. In general, the treatment in the control group, according to the results of the study at 6 months and 3 years follow-up, contributed to a decrease in the activity of the apoptosis system, but these changes are not reliable for all investigated parameters.

After 3 years of treatment, compared with 6 months, the concentration of CD95+ lymphocytes in 23 patients decreased by 1.1–2.3%, in 6 cases it remained at the previous level and in 4 patients it increased by 0.4–0.9%. The number of annexin V+ lymphocytes in 25 patients decreased by 0.3–1.7%, in 3 of them it increased by 0.3–0.9% and in 5 cases it did not change. There was also a decrease in the activity of proinflammatory cytokines. In particular, the concentration of TNF-α in 19 patients decreased by 0.3–1.9 pg/mL, in 9 cases it increased by 0.2–0.5 pg/mL and in 5 patients it remained unchanged; the content of INF-γ in 22 patients decreased by 0.3–1.8 pg/mL, in 4 of them it did not change and in 7 cases it increased by 0.3–0.6 pg/mL; the level of IL-1β in 25 patients decreased from 0.1–0.6 pg/mL, in 3 of them it remained unchanged, in other 5 it increased by 0.2–0.5 pg/mL. In general, the treatment in the control group, according to the results of the study at 6 months and 3 years follow-up, contributed to a decrease in the activity of the apoptosis system, but these changes are not reliable for all investigated parameters.

### Table 1. Indicators of peroxide oxidation of blood in patients with autoimmune thyroiditis before and after the treatment

<table>
<thead>
<tr>
<th>Value</th>
<th>Donors (n=25)</th>
<th>Control (n=20)</th>
<th>Main (n=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>On admission</td>
<td>After 6 months of treatment</td>
<td>After 3 years of treatment</td>
</tr>
<tr>
<td>MA, μmol/L</td>
<td>8.2±0.34</td>
<td>14.2±0.29 p*</td>
<td>12.8±0.12 p**</td>
</tr>
<tr>
<td>OMP u.o.d./g of protein</td>
<td>39.6±1.13</td>
<td>67.3±1.12 p*</td>
<td>62.2±1.18 p**</td>
</tr>
</tbody>
</table>

Note. p* - compared to donors, p** - compared to the values on admission, p*** - compared to the values after 6 months of treatment, p<0.05.

### Table 2. The rates of blood antioxidant defense in patients with AIT before and after the treatment

<table>
<thead>
<tr>
<th>Value</th>
<th>Donors (n=25)</th>
<th>Control (n=20)</th>
<th>Main (n=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>On admission</td>
<td>After 6 months of treatment</td>
<td>After 3 years of treatment</td>
</tr>
<tr>
<td>Catalase, μmol/min • g of Hb</td>
<td>168.7±3.40</td>
<td>128.5±3.69 p*</td>
<td>134.7±3.19</td>
</tr>
<tr>
<td>Ceruloplasmin, u.o.d./g of protein</td>
<td>77.2±2.61</td>
<td>42.1±2.87 p*</td>
<td>46.8±2.12</td>
</tr>
<tr>
<td>GPx, μmol/min • g of Hb</td>
<td>205.0±3.73</td>
<td>142.3±3.88 p*</td>
<td>148.6±3.81</td>
</tr>
</tbody>
</table>

Note. p* - compared to donors, p** - compared to values on admission, p*** - compared to values after 6 months of treatment, p<0.05.
Regarding apoptosis in patients from the study group, after 6 months of treatment, the content of CD95+ lymphocytes in 31 patients decreased by 3.5 – 11.2% and in 2 cases remained similar with the values before the treatment; the number of annexin V+ lymphocytes increased in all patients by 1.7 – 5.2%. The activity of pro-inflammatory cytokines decreased. For instance, the TNF-α content in all cases decreased by 0.6 – 3.5 pg/mL; the concentration of INF-γ in all patients also decreased by 1.9 – 7.8 pg/mL; the level of IL-1β in 26 patients decreased by 1.9 – 7.8 pg/mL, and in 7 cases it did not change. After 3 years of treatment, compared with those at inclusion, the changes in the number of annexin V+ lymphocytes (Table 3, p<0.05). Regarding apoptosis, it should be noted that the treatment of patients from the main group using thyroxin, lymph drainage and antioxidant therapy leads to a reliable decrease in the activity of apoptotic processes in the thyroid gland.

To assess the effectiveness of the proposed antioxidant and lymph drainage therapy in both groups of patients, the changes in the volume of the thyroid gland, the level of AbTPO and the dose of substitution therapy with L-thyroxine were compared before and after the treatment. An increase or decrease in the dose of substitution therapy reflects the level of hormones-producing function of thyroid gland.

In 12 patients from the control group, a decrease in thyroid volume was observed by 1.8 – 2.5 cm³ six months after the substitution therapy, and in 8 patients an increase in thyroid volume by 1.3 – 1.8 cm³. In general, the volume of the thyroid gland in the control group, compared with those on admission, according to the mean values (M ± m) for 6 months, decreased from 23.1 to 22.2 cm³, the changes being significant (p <0.05). After 3 years, the volume of the thyroid gland in 15 patients increased from 4.8 to 10.4 cm³ and in 5 patients it decreased from 2.8 to 4.1 cm³. The thyroid gland looked spotted, with hyperechogenicity of the tissue and multiple connective tissue elements. Solitary nodules (according to the results of puncture biopsy from nodal colloid goiter) were diagnosed in four patients and pseudo nodules in three cases. After 3 years, in the control group, the mean volume of the thyroid gland increased by 5.1 cm³ compared to the values at 6 months (p <0.05).

Ultrasound examination found a decrease in the volume of the thyroid gland, from 1.7 to 3.2 cm³ in 25 patients of the study group, in 3 cases an increase from 1.4 to 3.7 cm³ and in 5 cases the volume of the gland did not change. In general, the mean values (M ± m) of the volume of the thyroid gland in the study group at 6 months, compared with those at inclusion, decreased significantly. Three years later, the volume of the gland decreased from 0.9 to 1.5 cm³ in 27 patients, in 4 cases it increased by 1.7 to 3.3 cm³ and in 2 patients did not change compared with the values before the treatment.

Table 3. Peripheral blood lymphocyte apoptosis and concentration of TNF-α, INF-γ and IL-1β in blood serum from donors and patients with autoimmune thyroiditis, before and after treatment.

<table>
<thead>
<tr>
<th>Values</th>
<th>Donors (n=25)</th>
<th>Control (n=20)</th>
<th>Main (n=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD95+ lymphocytes,%</td>
<td>11.6 ±0.58</td>
<td>25.1±0.65 p*</td>
<td>24.9±0.61 p*</td>
</tr>
<tr>
<td>Number of annexin V+ lymphocytes,%</td>
<td>17.5 ±0.39 p*</td>
<td>12.8 ±0.31 p*</td>
<td>12.9 ±0.28 p*</td>
</tr>
<tr>
<td>Concentration of TNF-α, pg/mL</td>
<td>1.6 ±0.27 p*</td>
<td>5.2 ±0.24 p*</td>
<td>5.2 ±0.29 p*</td>
</tr>
<tr>
<td>Concentration of INF-γ, pg/mL</td>
<td>1.3 ±0.11 p*</td>
<td>10.5 ±0.29 p*</td>
<td>10.5 ±0.28 p*</td>
</tr>
<tr>
<td>Concentration of IL-1β, pg/mL</td>
<td>1.9 ±0.13 p*</td>
<td>4.8 ±0.17 p*</td>
<td>4.7 ±0.16 p*</td>
</tr>
</tbody>
</table>

Note. p* compared to donors, p** – compared to the values on admission, p*** – compared to the values after 6 months of treatment, p<0.05.
for a period of six months of treatment. In 2 patients, the increase of the thyroid volume was associated with nodules: in one case, a true nodule in volume of 0.6 cm³ (based on the results of the puncture biopsy it was nodal colloidal goiter), and in the second case, a pseudo nodule up to 0.7 cm³. At ultrasonography, the structure of the thyroid gland was homogeneous, with a small amount of connective tissue elements, the echogenicity of the gland was moderately diffuse - reduced.

The level of AbTPO in patients from the control group, after 6 months of treatment, decreased in 5 patients by 9‑16 U/mL, in 4 cases increased by 7‑12 U/mL and in other 11 patients did not change. The examination after three years of treatment found that the level of AbTPO in 12 patients decreased by 6‑18 U/mL, in 3 cases did not change and in other 5 increased by 9‑18 U/mL.

The patients in the study group showed a reliable decrease of the mean values of AbTPO compared with admission, after 6 months of treatment. In 28 cases, the level of antibodies decreased from 67 to 139 U/mL, in 2 patients increased by 35 and 42 U/mL and in 3 cases it remained unchanged. After three years of treatment, compared to the 6 months follow-up, a significant decrease of AbTPO was also observed: in 27 cases it decreased from 35 to 82 U/mL, in 4 cases remained unchanged, and in 2 cases ranged between 19 and 25 U/mL.

The dose of substitution therapy with thyroxine, after 6 months of treatment, in 11 patients from the control group, did not change, in 4 cases it decreased by 12.5 micrograms and in 5 patients it increased by 25 micrograms per day. After three years of treatment, the dose of substitution therapy in all patients increased in some cases by 12.5 – 50 micrograms per day (Table 4).

In patients of the study group, the dose of substitution therapy for the period of six months of treatment in 4 cases did not change, in 26 patients it decreased by 12.5 and in 3 cases it increased by 12.5 micrograms per day. After 3 years of treatment, in 13 patients the dose of substitution therapy decreased in some cases by 12.5 or 25 micrograms per day, in 18 patients it remained the same, and in 2 patients the substitution therapy was not expedient (Table 4, p <0.05).

**Conclusions**

Comprehensive treatment of patients suffering from AIT with hypothyroidism with the use of thyroxine, antioxidant and lymph drainage therapy improves the structure of the gland. This treatment reduces the activity of peroxide oxidation and pro-inflammatory cytokines, increases the level of antioxidant protection enzymes, normalizes the number of aniline-positive lymphocytes and improves lymphatic drainage and hormone-producing function of the gland.

**Compliance with Ethics Requirements:**

"The authors declare no conflict of interest regarding this article"

"The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from all the patients included in the study"

"No funding for this study"